THE YOTTABIT ERA / WHEN BREAKTHROUGHS COLLIDE

What if we could design medicines instead of finding them by chance?

Imagine a researcher describing the exact biological job a treatment needs to perform, then designing a protein to try doing it.

THE EXTRAORDINARY POSSIBILITY ↓WHAT IT COULD MEAN FOR YOU ↓
HERE'S WHY THIS IS SUCH A BIG DEAL

Medicine could move toward purposeful molecular design. The distance from an idea to a safe, approved treatment is still long—but the starting point is changing.

THE STORY IN PLAIN ENGLISH

Think of proteins as tiny machines that perform much of the work inside our bodies. For a long time, scientists had to discover their shapes through difficult experiments before they could begin to understand how they behaved. Computer systems can now predict enormous numbers of protein structures, giving researchers new starting points for the search for treatments. They are also beginning to design proteins with particular jobs in mind. The remarkable possibility is that future medicines could be built for specific biological tasks rather than found largely through trial and error. But every promising design still needs careful testing to prove it actually works and is safe.

THE YOTTABIT PERSPECTIVE

What does it mean to me?

Big change is fascinating. Its implications are what matter.

My life & career

Imagine a medicine designed to interact with a precise biological target rather than relying on a long search for something that might work. This is a promising direction of research—not a cure on demand.

My business

Drug developers may be able to search more potential designs and focus experiments on better candidates. Success will still be measured in safe, effective treatments, not the number of structures generated.

My industry

Pharma, biotechnology and diagnostics may see parts of their discovery processes redesigned around AI and automated experiments. The opportunity is speed with better evidence.

FROM JIM CARROLL’S WORK

Jim has discussed the shift from reactive healthcare to predictive and increasingly personalized medicine throughout his work with healthcare and life-science organizations.

Meet the futurist behind YottaBit ↗
WHAT COULD I DO MONDAY MORNING?

Look at one difficult disease. What specific experiment would show whether a new designed protein actually helps?

CURIOUS ABOUT THE SCIENCE?

The story is exciting.
The evidence still matters.

Here's what researchers have demonstrated, what's still ahead, and where to check the source. It should deepen the story—not get in the way of understanding it.

Behind the breakthrough THE EVIDENCE +

What's happening today: 200m+ structure predictions enlarge hypothesis space.

The next challenge: A predicted protein is not a treatment. It still has to work in living systems and survive clinical testing.

How the technologies connect: Structure prediction + protein design + high-throughput wet labs.

Explore the original research

EMBL-EBI & DeepMind — AlphaFold Protein Structure Database ↗

Our evidence and sourcing approach ↗

YOTTABIT V4.1.1 · 20261009-GRADE12-FIX1